<DOC>
	<DOCNO>NCT00931879</DOCNO>
	<brief_summary>The objective study determine efficacy 6 month 4 g/day oral Lovaza® endothelial-dependent heat-induced vasodilation type 2 diabetic neuropathy elevate triglyceride level . Omega-3 fatty acid appear exert beneficial effect vascular function independent change serum triglyceride . The efficacy compare placebo give duration . Efficacy drug evaluate 3 6 month treatment . This timeline adequate evaluation primary neurophysiological endpoint . Previously , investigator demonstrate feasible pharmacologically alter nerve fiber density little 18 week correlate subjective objective measure neurovascular function . The investigator predict enhancement post-ischemic hyperemia foot dorsum , dilative mechanism primarily endothelium-dependent similar improvement heat-induced hyperemia .</brief_summary>
	<brief_title>Lovaza® Microvascular Function Type 2 Diabetes</brief_title>
	<detailed_description>This pilot study within-subject repeated measure design . This study compare neurophysiological vascular response placebo treatment Lovaza® ( omega-3-acid ethyl ester , Reliant Pharmaceuticals , Inc. ) subject type 2 diabetes , neuropathy , dyslipidemia . Lovaza 's potential mechanism action inhibition acyl CoA:1 , 2-diacylglycerol acyltransferase increase peroxisomal β-oxidation liver . Subjects recruit baseline physiological , neurological hematological profile establish patient . Forty-four subject ( 20 active arm , 20 placebo arm , 2 replacement arm ) receive 4 g/day Lovaza® tablet placebo period 6 month . All subject receive physical neurological exam well neurovascular function test . This include nerve conduction study , quantitative sensory testing , quantitative autonomic testing , skin blood flow testing , include , ischemia reperfusion . Lab test include insulin resistance profile , hepatic renal function profile , lipid profile , C-reactive protein , thyroid stimulate hormone , fatty acid . Other test include inflammatory marker adiponectin TNF-α . The study power detect difference microvascular function 6 month Lovaza® difference ethnic response .</detailed_description>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>1 . Subjects may males nonpregnant , nonlactating female age 1880 year . 2 . Subjects must diagnose type 2 diabetes mellitus accord current ADA criterion . 3 . Triglyceride level 149 mg/dL 4 . Minimum 2 year diagnosis type 2 diabetes 5 . Prior participation study , subject must sign informed consent document . 1 . Presence type 1 diabetes mellitus ( define Cpeptide &lt; 1 ng/ml diabetes onset &lt; 35 year age nonobese patient ) . 2 . Presence diabetic retinopathy severe `` background '' level . 3 . Presence diabetic nephropathy , define urine dipstick result great 300 mg/100 mL protein ( proteinuria ) . 4 . Presence clinically significant neuropathy clearly nondiabetic origin , e.g . alcoholic autoimmune . 5 . Bilateral amputation low extremity foot ulcer involve great toe . Presence neuroarthropathy ( Charcot deformity ) allowable . 6 . History major macrovascular event myocardial infarction stroke . 7 . Participation another clinical trial concurrently within 30 day prior entry study . 8 . The use ACEinhibiting agent angiotensin receptor blockade therapy ( ARB ) allow must stable least 30 day prior study entry may change course study . This prudent due potential effect blood flow . 9 . Patients moderate severe hepatic insufficiency abnormality liver function define liver enzymes ( AST , ALT , alkaline phosphatase ) great 3 time upper limit normal . 10 . Presence pedal edema . 11 . Presence history heart failure NYHA Class II great . 12 . Other serious medical condition opinion investigator , would compromise subject 's participation study . 13 . Concomitant use medication know exacerbate triglyceride level , estrogen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>